28 results on '"Meunier, B."'
Search Results
2. POS1185 IRON DEFICIENCY IN FAMILIAL MEDITERRANEAN FEVER: A STUDY ON 211 ADULT PATIENTS FROM THE JIR COHORT
- Author
-
DI Cola, I., primary, Savey, L., additional, Delplanque, M., additional, Bourguiba, R., additional, Bartoli, A., additional, Aknouche, Z., additional, Bensalek, F., additional, Koné-Paut, I., additional, Rossi-Semerano, L., additional, Melki, I., additional, Bader-Meunier, B., additional, Neven, B., additional, Quartier, P., additional, Boursier, G., additional, Giurgea, I., additional, Cuisset, L., additional, Grateau, G., additional, Hentgen, V., additional, and Georgin-Lavialle, S., additional
- Published
- 2024
- Full Text
- View/download PDF
3. POS0378 HETEROZYGOUS LOSS-OF-FUNCTION RELA MUTATIONS LEAD TO SYSTEMIC LUPUS ERYTHEMATOSUS OR AUTOINFLAMMATORY SYNDROME
- Author
-
Riller, Q., primary, Barnabei, L., additional, Rodrigo-Riestra, M., additional, Stolzenberg, M. C., additional, Pelle, O., additional, Delage, L., additional, Becquard, T., additional, Courteille, C., additional, Marchais, M., additional, De Cevins, C., additional, Brunaud, C., additional, Magerus, A., additional, Luka, M., additional, Sorin, B., additional, Boussard, C., additional, Salomon, R., additional, Ménager, M., additional, Hié, M., additional, Neven, B., additional, Baud, V., additional, Skokowa, J., additional, Sogkas, G., additional, Jamilloux, Y., additional, Merlin, E., additional, Belot, A., additional, Picard, C., additional, Boursier, G., additional, Riviere, E., additional, Georgin-Lavialle, S., additional, Quartier, P., additional, Bader-Meunier, B., additional, Fischer, A., additional, Miner, J. J., additional, and Rieux-Laucat, F., additional
- Published
- 2024
- Full Text
- View/download PDF
4. POS0221 CLUSTER ANALYSIS IDENTIFIES THREE CLINICAL PATTERNS OF PATIENTS WITH ANTI-KU ANTIBODIES: A MULTICENTRE STUDY OF 154 PATIENTS.
- Author
-
Robert, M., primary, Nguyen, Y., additional, Allenbach, Y., additional, Sacre, K., additional, Terrier, B., additional, Borie, R., additional, Uzunhan, Y., additional, Amoura, Z., additional, Comparon, C., additional, Dieudé, P., additional, Le Guern, V., additional, Morélot-Panzini, C., additional, Humbert, M., additional, Sitbon, O., additional, Goujard, C., additional, Bader-Meunier, B., additional, Fautrel, B., additional, Chrétien, P., additional, Roland-Nicaise, P., additional, Goulvestre, C., additional, Charuel, J. L., additional, Benveniste, O., additional, Mouthon, L., additional, De Lastours, V., additional, Dusser, P., additional, Zaidan, M., additional, Aslangul, E., additional, Saillour, M., additional, Dingulu, G., additional, Chasset, F., additional, Nocturne, G., additional, Mariette, X., additional, Bitoun, S., additional, and Seror, R., additional
- Published
- 2024
- Full Text
- View/download PDF
5. POS1184 THE TRANSITION TO ADULT CARE IN AUTOINFLAMMATORY DISEASES: A COHORT OF 112 FRENCH PATIENTS
- Author
-
Elhani, I., primary, Hentgen, V., additional, Quartier, P., additional, Melki, I., additional, Bader-Meunier, B., additional, Neven, B., additional, Koné-Paut, I., additional, Rossi-Semerano, L., additional, Meinzer, U., additional, Grateau, G., additional, Savey, L., additional, and Georgin-Lavialle, S., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Suprapubic versus transurethral catheterization for bladder drainage in male rectal cancer surgery (GRECCAR10), a randomized clinical trial.
- Author
-
Trilling, B., Tidadini, F., Lakkis, Z., Jafari, M., Germain, A., Rullier, E., Lefevre, J., Tuech, J. J., Kartheuser, A., Leonard, D., Prudhomme, M., Piessen, G., Regimbeau, J. M., Cotte, E., Duprez, D., Badic, B., Panis, Y., Rivoire, M., Meunier, B., and Portier, G.
- Subjects
RECTAL cancer ,RECTAL surgery ,URINARY catheterization ,ONCOLOGIC surgery ,MEDICAL drainage ,CLINICAL trials ,CATHETERIZATION - Abstract
Background: Bladder drainage is systematically used in rectal cancer surgery; however, the optimal type of drainage, transurethral catheterization (TUC) or suprapubic catheterization (SPC), is still controversial. The aim was to compare the rates of urinary tract infection on the fourth postoperative day (POD4) between TUC and SPC, after rectal cancer surgery regardless of the day of removal of the urinary drain. Methods: This randomized clinical trial in 19 expert colorectal surgery centers in France and Belgium was performed between October 2016 and October 2019 and included 240 men (with normal or subnormal voiding function) undergoing mesorectal excision with low anastomosis for rectal cancer. Patients were followed at postoperative days 4, 30, and 180. Results: In 208 patients (median age 66 years [IQR 58–71]) randomized to TUC (n = 99) or SPC (n = 109), the rate of urinary infection at POD4 was not significantly different whatever the type of drainage (11/99 (11.1%) vs. 8/109 (7.3%), 95% CI, − 4.2% to 11.7%; p = 0.35). There was significantly more pyuria in the TUC group (79/99 (79.0%) vs. (60/109 (60.9%), 95% CI, 5.7–30.0%; p = 0.004). No difference in bacteriuria was observed between the groups. Patients in the TUC group had a shorter duration of catheterization (median 4 [2–5] vs. 4 [3–5] days; p = 0.002). Drainage complications were more frequent in the SPC group at all followup visits. Conclusions: TUC should be preferred over SPC in male patients undergoing surgery for mid and/or lower rectal cancers, owing to the lower rate of complications and shorter duration of catheterization. Trial registration: ClinicalTrials.gov identifier NCT02922647. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Mutations de UNC93B1 : une nouvelle cause de lupus érythémateux systémique et de lupus-engelures monogéniques
- Author
-
David, C., Arango-Franco, C., Badony, M., Fouchet, J., Rice, G., Didry-Barca, B., Maisonneuve, L., Seabra, L., Kechiche, R., Masson, C., Cobat, A., Abel, L., Talouarn, E., Beziat, V., Deswarte, C., Livingstone, K., Paul, C., Malik, G., Ross, A., Adam, J., Walsch, J., Kumar, S., Bonnet, D., Bodemer, C., Bader-Meunier, B., Marsch, J., Crow, Y., Casanova, J.L., Manoury, B., Frémond, M.L., Bohlen, J., and Lepelley, A.
- Published
- 2024
- Full Text
- View/download PDF
8. A quick response, but not too much: Experienced mangabeys (Cercocebus torquatus) lose interest in contact call exchanges that do not respect this "conversational rule".
- Author
-
Meunier B, Durier V, Rossard A, and Lemasson A
- Subjects
- Animals, Male, Social Behavior, Reaction Time physiology, Vocalization, Animal physiology, Cercocebus physiology
- Abstract
Several non-human primate species engage in vocal exchanges of contact calls, throughout the day in peaceful contexts. These vocal exchanges have been compared to human conversations because vocalizations are uttered in turn-taking: a temporal pattern where interlocutors minimize silences and avoid overlaps. But observing such a pattern in the spontaneous production of a species, as is the case with red-capped mangabeys (Cercocebus torquatus), is not enough to make it a rule. Another prerequisite is that the pattern is expected by the animal. Here, we conducted a playback experiment using the violation-of-expectation paradigm to test whether captive red-capped mangabeys react differently to usual vs unusual interactive temporal patterns. We played back vocal exchanges with usual minimized response time (0.5 sec), with unusual longer response time (1.5 sec) and with unusual call overlap to 12 adult captive male mangabeys. For each individual, we measured the occurrences and durations of head orientation toward the loudspeaker after the stimuli. The interest of individuals varied according to the vocal exchange temporal pattern in interaction with their age. Indeed, the older (and thus more socially experienced) an individual was, the less interested he became after an unusual vocal exchange, i.e. a vocal exchange with call overlap or with a delayed response time. These findings suggest that experience shapes attention towards more socially relevant situations, and thus that turn-taking can be qualified as a social rule., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Meunier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
9. Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.
- Author
-
Saper VE, Tian L, Verstegen RHJ, Conrad CK, Cidon M, Hopper RK, Kuo CS, Osoegawa K, Baszis K, Bingham CA, Ferguson I, Hahn T, Horne A, Isupova EA, Jones JT, Kasapcopur Ö, Klein-Gitelman MS, Kostik MM, Ozen S, Phadke O, Prahalad S, Randell RL, Sener S, Stingl C, Abdul-Aziz R, Akoghlanian S, Al Julandani D, Alvarez MB, Bader-Meunier B, Balay-Dustrude EE, Balboni I, Baxter SK, Berard RA, Bhattad S, Bolaria R, Boneparth A, Cassidy EA, Co DO, Collins KP, Dancey P, Dickinson AM, Edelheit BS, Espada G, Flanagan ER, Imundo LF, Jindal AK, Kim HA, Klaus G, Lake C, Lapin WB, Lawson EF, Marmor I, Mombourquette J, Ogunjimi B, Olveda R, Ombrello MJ, Onel K, Poholek C, Ramanan AV, Ravelli A, Reinhardt A, Robinson AD, Rouster-Stevens K, Saad N, Schneider R, Selmanovic V, Sefic Pasic I, Shenoi S, Shilo NR, Soep JB, Sura A, Taber SF, Tesher M, Tibaldi J, Torok KS, Tsin CM, Vasquez-Canizares N, Villacis Nunez DS, Way EE, Whitehead B, Zemel LS, Sharma S, Fernández-Viña MA, and Mellins ED
- Subjects
- Humans, Female, Male, Child, Adolescent, Child, Preschool, Infant, Drug Hypersensitivity Syndrome, Interleukin-6 antagonists & inhibitors, Interleukin-1 antagonists & inhibitors
- Abstract
Background: After introducing IL-1/IL-6 inhibitors, some patients with Still and Still-like disease developed unusual, often fatal, pulmonary disease. This complication was associated with scoring as DReSS (drug reaction with eosinophilia and systemic symptoms) implicating these inhibitors, although DReSS can be difficult to recognize in the setting of systemic inflammatory disease., Objective: To facilitate recognition of IL-1/IL-6 inhibitor-DReSS in systemic inflammatory illnesses (Still/Still-like) by looking at timing and reaction-associated features. We evaluated outcomes of stopping or not stopping IL-1/IL-6 inhibitors after DReSS reaction began., Methods: In an international study collaborating primarily with pediatric specialists, we characterized features of 89 drug-reaction cases versus 773 drug-exposed controls and compared outcomes of 52 cases stopping IL-1/IL-6 inhibitors with 37 cases not stopping these drugs., Results: Before the reaction began, drug-reaction cases and controls were clinically comparable, except for younger disease-onset age for reaction cases with preexisting cardiothoracic comorbidities. After the reaction began, increased rates of pulmonary complications and macrophage activation syndrome differentiated drug-reaction cases from drug-tolerant controls (P = 4.7 × 10
-35 and P = 1.1 × 10-24 , respectively). The initial DReSS feature was typically reported 2 to 8 weeks after initiating IL-1/IL-6 inhibition. In drug-reaction cases stopping versus not stopping IL-1/IL-6-inhibitor treatment, reaction-related features were indistinguishable, including pulmonary complication rates (75% [39 of 52] vs 76% [28 of 37]). Those stopping subsequently required fewer medications for treatment of systemic inflammation, had decreased rates of macrophage activation syndrome, and improved survival (P = .005, multivariate regression). Resolution of pulmonary complications occurred in 67% (26 of 39) of drug-reaction cases who stopped and in none who continued inhibitors., Conclusions: In systemic inflammatory illnesses, recognition of IL-1/IL-6-inhibitor-associated reactions followed by avoidance of IL-1/IL-6 inhibitors significantly improved outcomes., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
10. Of the importance to reconsider individual variability in infant studies: Family traits do impact turn-taking perception in 6-month-olds.
- Author
-
Meunier B, Barbu S, Rabiller A, Dollion N, Lemasson A, and Durier V
- Subjects
- Humans, Infant, Female, Male, Individuality, Infant Behavior, Family, Language Development
- Abstract
Turn-taking is a universal pattern of human conversations characterized by a fast exchange of turns between speakers and an avoidance of overlaps. Language is embedded in this conversational skill acquired well before it during infancy, through everyday interactions with caregivers. The earliness of this skill and its link with language allows us to test whether social environment shapes early language development. We therefore study turn-taking perception of 6-month-old infants by measuring their gazes during video presentation of three different conversational situations where the turn is explicitly given, normally taken or taken with an overlap. We studied 51 infants to cover several family and infant characteristics: infants' sex, presence of siblings, and family socioeconomic status (SES). We found that infants looked more at the second speaker when she overlapped the first speaker than in the other situations, but not all infants were equally sensitive. Indeed, infants from high-SES families reacted differently to the three situations, while infants from the two lower SES categories did not. Also, only singletons reacted differently by looking more at the second speaker after the overlapping and turn-giving situations, and not after the turn-taking situation. Our results emphasize the importance of early social experiences on language development., (© 2024 The Author(s). Infancy published by Wiley Periodicals LLC on behalf of International Congress of Infant Studies.)
- Published
- 2024
- Full Text
- View/download PDF
11. Comment on: Long-term outcomes of childhood-onset systemic lupus erythematosus: Reply.
- Author
-
Bader-Meunier B, Mirguet A, and Aeschlimann FA
- Published
- 2024
- Full Text
- View/download PDF
12. TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients.
- Author
-
Nguyen HD, Jouen F, Déchelotte B, Cordel N, Gitiaux C, Bodemer C, Quartier P, Belot A, O'Brien K, Cancemi D, Melki I, Fabien N, Tansley S, Boyer O, Wedderburn LR, and Bader-Meunier B
- Subjects
- Humans, Female, Child, Male, Neoplasms immunology, Transcription Factors immunology, Transcription Factors genetics, Adolescent, Child, Preschool, Dermatomyositis immunology, Immunoglobulin G immunology, Immunoglobulin G blood
- Published
- 2024
- Full Text
- View/download PDF
13. Transition to Adult Care in Autoinflammatory Diseases: A Cohort of 111 French Patients.
- Author
-
Elhani I, Hentgen V, Quartier P, Bader-Meunier B, Kone-Paut I, Neven B, Rossi L, Faye A, Meinzer U, Melki I, Grateau G, Savey L, and Georgin-Lavialle S
- Subjects
- Humans, Female, Male, Adult, France, Adolescent, Young Adult, Hereditary Autoinflammatory Diseases therapy, Hereditary Autoinflammatory Diseases diagnosis, Referral and Consultation statistics & numerical data, Referral and Consultation organization & administration, Familial Mediterranean Fever therapy, Familial Mediterranean Fever diagnosis, Familial Mediterranean Fever physiopathology, Retrospective Studies, Transition to Adult Care organization & administration
- Abstract
Background: Transitioning from pediatric to adult care is a critical step for individuals with autoinflammatory diseases, requiring effective programs to ensure continuity of care and disease management. Despite various recommendations, the effectiveness of transition programs, particularly in monogenic autoinflammatory diseases, remains understudied., Methods: A single-center medical records review study was conducted at the French National Reference Center for Adult Autoinflammatory Diseases in Tenon Hospital from 2017 to 2023. All patients who had consulted for the first time between the ages of 15 and 30 years and had received care for an autoinflammatory disease during childhood were included. The patients were classified according to whether they had undergone a transition, defined as either no transition, simple transition (referral letter), or joint transition (pediatrician and adult physician consultation)., Results: One hundred eleven patients (median age, 18 years) were included. Patients who consulted without transition started adult follow-up and were followed up less regularly than those who underwent the transition process ( p < 0.001 and p = 0.028). In patients with familial Mediterranean fever, the absence of a formal transition was associated with poorer disease control at baseline ( p = 0.019). The type of transition did not impact disease control during follow-up., Conclusions: Participation in a transition program is associated with earlier and more regular follow-up in adulthood. Although transition type did not significantly impact disease control during follow-up in familial Mediterranean fever, the potential benefit of joint consultation extends beyond consultation frequency and disease outcomes, encompassing patient perspectives and self-management abilities. This study highlights the significance of collaborative transition programs in AIDs., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. French protocol for the diagnosis and management of systemic lupus erythematosus.
- Author
-
Amoura Z, Bader-Meunier B, Antignac M, Bardin N, Belizna C, Belot A, Bonnotte B, Bouaziz JD, Chasset F, Chiche L, Cohen F, Costedoat-Chalumeau N, Daugas E, Devilliers H, Diot E, Elefant E, Faguer S, Ferreira N, Hachulla E, Hanslik T, Hie M, Jourde-Chiche N, Le Guern V, Martin T, Mathian A, Michel M, Miyara M, Papo T, Richez C, Scherlinger M, Sibilia J, Uzunhan Y, Wahl D, Wojtasik G, and Yelnik C
- Subjects
- Humans, France epidemiology, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Clinical Protocols, Female, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic therapy, Lupus Erythematosus, Systemic complications
- Abstract
Because Systemic Lupus Erythematosus (SLE) is a rare disease, and due to the significant prognostic impact of early management, a diagnosis confirmed by a physician with experience in SLE is recommended, for example from an expert center. Once the diagnosis is confirmed, existing manifestations should be identified in particular, renal involvement by an assessment of proteinuria, disease activity and severity should be determined, potential complications anticipated, associated diseases searched for, and the patient's socioprofessional and family context noted. Therapeutic management of SLE includes patient education on recognizing symptoms, understanding disease progression as well as when they should seek medical advice. Patients are informed about routine checkups, treatment side effects, and the need for regular vaccinations, especially if they are receiving immunosuppressive treatment. They are also advised on lifestyle factors such as the risks of smoking, sun exposure, and dietary adjustments, especially when they are receiving corticosteroids. The importance of contraception, particularly when teratogenic medications are being used, and regular cancer screening are emphasized. Support networks can help relieve a patient's isolation. The first-line medical treatment of SLE is hydroxychloroquine (HCQ), possibly combined with an immunosuppressant and/or low-dose corticosteroid therapy. The treatment of flares depends on their severity, and typically involves HCQ and NSAIDs, but may be escalated to corticosteroid therapy with immunosuppressants or biologic therapies in moderate to severe cases. Because there is no curative treatment, the goals of therapy are patient comfort, preventing progression and flares, and preserving overall long-term health and fertility. The frequency of follow-up visits depends on disease severity and any new symptoms. Regular specialized assessments are necessary, especially when treatment changes, but a frequency of every 3 to 6 months is recommended during periods of remission and monthly during active or severe disease, especially in children. These assessments include both clinical and laboratory tests to monitor complications and disease activity, with specific attention to proteinuria., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
15. Homozygous variant in TKFC abolishing triokinase activities is associated with isolated immunodeficiency.
- Author
-
Tremblay-Laganière C, Michaud C, Abourjaili-Bilodeau R, Cabezas A, Canales J, Costas MJ, Ribeiro JM, Leclerc-Blain J, Touzot F, Haddad E, Teira P, Duval M, Onoufriadis A, Meunier B, Cameselle JC, and Campeau PM
- Subjects
- Female, Humans, Male, Epstein-Barr Virus Infections genetics, Epstein-Barr Virus Infections virology, Epstein-Barr Virus Infections complications, Exome Sequencing, Immunologic Deficiency Syndromes genetics, Immunologic Deficiency Syndromes pathology, Mutation genetics, Phosphotransferases (Alcohol Group Acceptor) genetics, Infant, Newborn, Infant, Child, Preschool, Child, Homozygote
- Abstract
Background: Triokinase and FMN cyclase (TKFC) is a bifunctional enzyme involved in fructose metabolism. Triokinase catalyses the phosphorylation of fructose-derived glyceraldehyde (GA) and exogenous dihydroxyacetone (DHA), while FMN cyclase generates cyclic FMN. TKFC regulates the antiviral immune response by interacting with IFIH1 (MDA5). Previously reported pathogenic variants in TKFC are associated with either a multisystemic disease or isolated hypotrichosis with loose anagen hairs., Methods: Whole-exome sequencing identified a homozygous novel variant in TKFC (c.1624G>A; p.Gly542Arg) in an individual with a complex primary immunodeficiency disorder. The variant was characterised using enzymatic assays and yeast studies of mutant recombinant proteins., Results: The individual presented with chronic active Epstein-Barr virus disease and multiple bacterial and viral infections. Clinical investigations revealed hypogammaglobulinaemia, near absent natural killer cells and decreased memory B cells. Enzymatic assays showed that this variant displayed defective DHA and GA kinase activity while maintaining FMN cyclase activity. An allogenic bone marrow transplantation corrected the patient's immunodeficiency., Conclusion: Our report suggests that TKFC may have a role in the immunological system. The pathological features associated with this variant are possibly linked with DHA/GA kinase inactivation through a yet an unknown mechanism. This report thus adds a possible new pathway of immunometabolism to explore further., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
16. Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation.
- Author
-
Triaille C, Rao NM, Rice GI, Seabra L, Sutherland FJH, Bondet V, Duffy D, Gennery AR, Fournier B, Bader-Meunier B, Troedson C, Cleary G, Buso H, Dalby-Payne J, Ranade P, Jansen K, De Somer L, Frémond ML, Chavan PP, Wong M, Dale RC, Wouters C, Quartier P, Khubchandani R, and Crow YJ
- Subjects
- Humans, Female, Male, Adult, Child, Adolescent, Young Adult, Signal Transduction, Middle Aged, Inflammation genetics, Interferon-alpha, Child, Preschool, Retrospective Studies, Complement C1q genetics, Complement C1q metabolism, Interferon Type I metabolism
- Abstract
Hereditary C1q deficiency (C1QDef) is a rare monogenic disorder leading to defective complement pathway activation and systemic lupus erythematosus (SLE)-like manifestations. The link between impairment of the complement cascade and autoimmunity remains incompletely understood. Here, we assessed type 1 interferon pathway activation in patients with C1QDef. Twelve patients with genetically confirmed C1QDef were recruited through an international collaboration. Clinical, biological and radiological data were collected retrospectively. The expression of a standardized panel of interferon stimulated genes (ISGs) in peripheral blood was measured, and the level of interferon alpha (IFNα) protein in cerebrospinal fluid (CSF) determined using SIMOA technology. Central nervous system (encompassing basal ganglia calcification, encephalitis, vasculitis, chronic pachymeningitis), mucocutaneous and renal involvement were present, respectively, in 10, 11 and 2 of 12 patients, and severe infections recorded in 2/12 patients. Elevated ISG expression was observed in all patients tested (n = 10/10), and serum and CSF IFNα elevated in 2/2 patients. Three patients were treated with Janus-kinase inhibitors (JAKi), with variable outcome; one displaying an apparently favourable response in respect of cutaneous and neurological features, and two others experiencing persistent disease despite JAKi therapy. To our knowledge, we report the largest original series of genetically confirmed C1QDef yet described. Additionally, we present a review of all previously described genetically confirmed cases of C1QDef. Overall, individuals with C1QDef demonstrate many characteristics of recognized monogenic interferonopathies: particularly, cutaneous involvement (malar rash, acral vasculitic/papular rash, chilblains), SLE-like disease, basal ganglia calcification, increased expression of ISGs in peripheral blood, and elevated levels of CSF IFNα., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus.
- Author
-
David C, Arango-Franco CA, Badonyi M, Fouchet J, Rice GI, Didry-Barca B, Maisonneuve L, Seabra L, Kechiche R, Masson C, Cobat A, Abel L, Talouarn E, Béziat V, Deswarte C, Livingstone K, Paul C, Malik G, Ross A, Adam J, Walsh J, Kumar S, Bonnet D, Bodemer C, Bader-Meunier B, Marsh JA, Casanova JL, Crow YJ, Manoury B, Frémond ML, Bohlen J, and Lepelley A
- Subjects
- Female, Humans, Male, Gain of Function Mutation, HEK293 Cells, Lupus Erythematosus, Cutaneous genetics, Lupus Erythematosus, Cutaneous pathology, Membrane Transport Proteins genetics, Membrane Transport Proteins metabolism, Mutation, Missense, Pedigree, Toll-Like Receptor 8 genetics, Toll-Like Receptor 8 metabolism, Child, Preschool, Child, Young Adult, Adult, Chilblains genetics, Lupus Erythematosus, Systemic genetics, Toll-Like Receptor 7 genetics, Toll-Like Receptor 7 metabolism
- Abstract
UNC93B1 is a transmembrane domain protein mediating the signaling of endosomal Toll-like receptors (TLRs). We report five families harboring rare missense substitutions (I317M, G325C, L330R, R466S, and R525P) in UNC93B1 causing systemic lupus erythematosus (SLE) or chilblain lupus (CBL) as either autosomal dominant or autosomal recessive traits. As for a D34A mutation causing murine lupus, we recorded a gain of TLR7 and, to a lesser extent, TLR8 activity with the I317M (in vitro) and G325C (in vitro and ex vivo) variants in the context of SLE. Contrastingly, in three families segregating CBL, the L330R, R466S, and R525P variants were isomorphic with respect to TLR7 activity in vitro and, for R525P, ex vivo. Rather, these variants demonstrated a gain of TLR8 activity. We observed enhanced interaction of the G325C, L330R, and R466S variants with TLR8, but not the R525P substitution, indicating different disease mechanisms. Overall, these observations suggest that UNC93B1 mutations cause monogenic SLE or CBL due to differentially enhanced TLR7 and TLR8 signaling., (© 2024 David et al.)
- Published
- 2024
- Full Text
- View/download PDF
18. Proteomic Profiling of Antimalarial Plasmodione Using 3-Benz(o)ylmenadione Affinity-Based Probes.
- Author
-
Iacobucci I, Monaco V, Hovasse A, Dupouy B, Keumoe R, Cichocki B, Elhabiri M, Meunier B, Strub JM, Monti M, Cianférani S, Blandin SA, Schaeffer-Reiss C, and Davioud-Charvet E
- Subjects
- Protozoan Proteins metabolism, Photoaffinity Labels chemistry, Photoaffinity Labels pharmacology, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae drug effects, Molecular Probes chemistry, Molecular Probes pharmacology, Proteome analysis, Proteome metabolism, Molecular Structure, Antimalarials pharmacology, Antimalarials chemistry, Plasmodium falciparum drug effects, Proteomics, Vitamin K 3 pharmacology, Vitamin K 3 chemistry, Vitamin K 3 metabolism
- Abstract
Understanding the mechanisms of drug action in malarial parasites is crucial for the development of new drugs to combat infection and to counteract drug resistance. Proteomics is a widely used approach to study host-pathogen systems and to identify drug protein targets. Plasmodione is an antiplasmodial early-lead drug exerting potent activities against young asexual and sexual blood stages in vitro with low toxicity to host cells. To elucidate its molecular mechanisms, an affinity-based protein profiling (AfBPP) approach was applied to yeast and P. falciparum proteomes. New (pro-) AfBPP probes based on the 3-benz(o)yl-6-fluoro-menadione scaffold were synthesized. With optimized conditions of both photoaffinity labeling and click reaction steps, the AfBPP protocol was then applied to a yeast proteome, yielding 11 putative drug-protein targets. Among these, we found four proteins associated with oxidoreductase activities, the hypothesized type of targets for plasmodione and its metabolites, and other proteins associated with the mitochondria. In Plasmodium parasites, the MS analysis revealed 44 potential plasmodione targets that need to be validated in further studies. Finally, the localization of a 3-benzyl-6-fluoromenadione AfBPP probe was studied in the subcellular structures of the parasite at the trophozoite stage., (© 2024 The Author(s). ChemBioChem published by Wiley-VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
19. Long-term outcomes of childhood-onset systemic lupus erythematosus.
- Author
-
Mirguet A, Aeschlimann FA, Lemelle I, Jaussaud R, Decker P, Moulinet T, Mohamed S, Quartier P, Hofer M, Boyer O, Belot A, Hummel A, Costedoat-Chalumeau N, and Bader-Meunier B
- Abstract
Objective: Data on the long-term outcome of patients with childhood-onset Systemic Lupus Erythematosus (cSLE) are scarce. Aims of this study were to describe the long-term outcomes of cSLE and to identify factors associated with the development of damage and persistent disease activity., Methods: We conducted a retrospective multicentre study using data from the PEDIALUP registry of the Juvenile Inflammatory Rheumatism (JIR) cohort database. Demographic characteristics, clinical manifestations, laboratory, radiological, histological and treatment data were collected from medical records during follow-up., Results: A total of 138 patients with cSLE, diagnosed between 1971 and 2015, were included. With a median follow-up of 15.4 [9.6-22.4] years, 51% of patients had a SLICC-Damage Index score ≥ 1 at last follow-up with the musculoskeletal, cutaneous, renal, neurological, and cardiovascular damage being the most common manifestations. The proportion of patients with a SLICC-DI score ≥ 1 increased significantly with the duration of the follow-up (p< 0.001). On multivariate analysis, duration of follow-up was associated with increased risk of cumulative damage (OR 1.08, 95% CI 1.01, 1.15, p= 0.035). At the last visit, 34% of patients still had active disease with a SLEDAI score of ≥ 6. On multivariate analysis, Sub-Saharan African ethnicity was associated with 7-fold increased odds of having active disease at the last visit compared with Caucasians (OR 7.44, 95% CI 2.24, 24.74, p= 0.0002)., Conclusion: The prevalence of damage remains high in patients with cSLE even when the diagnosis of c-SLE has been made in the recent decades., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
20. Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents.
- Author
-
Guan Y, Nguyen M, Robert A, Liu Y, and Meunier B
- Abstract
Cancer cell proliferation and metastasis are known to be dependent on angiogenesis which is regulated by several parameters including copper availability. Tetradentate monoquinoline (TDMQ) ligands constitute a series of chelators tailored to regulate copper homeostasis due to their specificity for copper(ii) with respect to Cu(i) or other biometals like iron or zinc. One of these chelators, TDMQ20 efficiently inhibits both proliferation and migration of several human cancer cell lines, better than the reference drug 5-fluorouracil, and with higher selectivity indexes with respect to non-cancer human cells. The biological activity of TDMQ20 may be driven by the coordination chemistry of copper, and the ability of this chelator to restore copper homeostasis and its subsequent redox properties. The anticancer mechanism of action of TDMQ20 involves intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of tumor cell apoptosis. These data support the selection of TDMQ20 as drug-candidate against several human cancers., Competing Interests: There are no conflicts to declare., (This journal is © The Royal Society of Chemistry.)
- Published
- 2024
- Full Text
- View/download PDF
21. Immuno-inflammatory involvement of adipose tissue in children.
- Author
-
Bader-Meunier B
- Subjects
- Humans, Child, Obesity immunology, Obesity complications, Adipose Tissue immunology, Adipose Tissue pathology, Inflammation immunology
- Abstract
Adipose tissue is a highly immunologically active tissue that can be involved in many inflammatory diseases. In this presentation, only adipose tissue disorders associated with inflammatory diseases in children will be described, with the exception of obesity., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
22. Synthesis and Anti-Chagas Activity Profile of a Redox-Active Lead 3-Benzylmenadione Revealed by High-Content Imaging.
- Author
-
Trometer N, Pecourneau J, Feng L, Navarro-Huerta JA, Lazarin-Bidóia D, de Oliveira Silva Lautenschlager S, Maes L, Fortes Francisco A, Kelly JM, Meunier B, Cal M, Mäser P, Kaiser M, and Davioud-Charvet E
- Subjects
- Animals, Humans, Mice, Trypanosoma cruzi drug effects, Oxidation-Reduction, Chagas Disease drug therapy, Trypanocidal Agents pharmacology, Trypanocidal Agents chemistry, Trypanocidal Agents chemical synthesis
- Abstract
Chagas disease, or American trypanosomiasis, is a neglected tropical disease which is a top priority target of the World Health Organization. The disease, endemic mainly in Latin America, is caused by the protozoan Trypanosoma cruzi and has spread around the globe due to human migration. There are multiple transmission routes, including vectorial, congenital, oral, and iatrogenic. Less than 1% of patients have access to treatment, relying on two old redox-active drugs that show poor pharmacokinetics and severe adverse effects. Hence, the priorities for the next steps of R&D include (i) the discovery of novel drugs/chemical classes, (ii) filling the pipeline with drug candidates that have new mechanisms of action, and (iii) the pressing need for more research and access to new chemical entities. In the present work, we first identified a hit ( 4a ) with a potent anti- T. cruzi activity from a library of 3-benzylmenadiones. We then designed a synthetic strategy to build a library of 49 3-(4-monoamino)benzylmenadione derivatives via reductive amination to obtain diazacyclic benz(o)ylmenadiones. Among them, we identified by high content imaging an anti-amastigote "early lead" 11b (henceforth called cruzidione) revealing optimized pharmacokinetic properties and enhanced specificity. Studies in a yeast model revealed that a cruzidione metabolite, the 3-benzoylmenadione (cruzidione oxide), enters redox cycling with the NADH-dehydrogenase, generating reactive oxygen species, as hypothesized for the early hit ( 4a ).
- Published
- 2024
- Full Text
- View/download PDF
23. Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.
- Author
-
Cosson C, Riou R, Patoli D, Niu T, Rey A, Groslambert M, De Rosny C, Chatre E, Allatif O, Henry T, Venet F, Milhavet F, Boursier G, Belot A, Jamilloux Y, Merlin E, Duquesne A, Grateau G, Savey L, Jacques Maria AT, Pagnier A, Poutrel S, Lambotte O, Mallebranche C, Ardois S, Richer O, Lemelle I, Rieux-Laucat F, Bader-Meunier B, Amoura Z, Melki I, Cuisset L, Touitou I, Geyer M, Georgin-Lavialle S, and Py BF
- Subjects
- Humans, Inflammasomes genetics, Drug Development, Syndrome, NLR Family, Pyrin Domain-Containing 3 Protein genetics, Gain of Function Mutation genetics
- Abstract
NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development., (© 2024 Cosson et al.)
- Published
- 2024
- Full Text
- View/download PDF
24. Antinuclear antibody-associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus.
- Author
-
Granel J, Fernandes H, Bader-Meunier B, Guth A, Richer O, Pillet P, Leverger G, Ducassou S, Fahd M, Pasquet M, Garnier N, Barlogis V, Guitton C, Jeziorski E, Thomas C, Bayart S, Cheikh N, Paillard C, Abou Chahla W, Chastagner P, Neven B, Millot F, Lejeune J, Li-Thiao Te V, Armari-Alla C, Briandet C, Carausu L, Deparis M, Piguet C, Benadiba J, Marie-Cardine A, Stephan JL, Pellier I, Pluchart C, Doré E, Michaux K, Héritier S, Leblanc T, and Aladjidi N
- Subjects
- Adolescent, Adult, Child, Humans, Young Adult, Antibodies, Antinuclear, Prospective Studies, Risk Factors, Cytopenia, Lupus Erythematosus, Systemic diagnosis
- Abstract
Abstract: Autoimmune cytopenia (AIC) in children may be associated with positive antinuclear antibodies (ANA) and may progress to systemic lupus erythematosus (SLE). We evaluated the risk of progression to SLE of childhood-onset ANA-associated AIC. In the French national prospective OBS'CEREVANCE cohort, the long-term outcome of children with ANA-associated AIC (ANA titer ≥1/160) and a subgroup of children who developed SLE were described. ANA were positive in 355 of 1803 (20%) children with AIC. With a median follow-up of 5.8 (range, 0.1-29.6) years, 79 of 355 (22%) patients developed SLE at a median age of 14.5 (1.1-21.4) years; 20% of chronic immune thrombocytopenic purpura, 19% of autoimmune hemolytic anemia, and 45% of Evans syndrome. None of the patients with ANA-negative test developed SLE. Severe manifestations of SLE were observed in 21 patients, and 2 patients died. In multivariate analysis including patients with positive ANA within the first 3 months after AIC diagnosis, age >10 years at AIC diagnosis (relative risk [RR], 3.67; 95% confidence interval [CI], 1.18-11.4; P = .024) and ANA titer >1/160 (RR, 5.28; 95% CI, 1.20-23.17; P = .027) were associated with the occurrence of SLE after AIC diagnosis. ANA-associated AIC is a risk factor for progression to SLE, especially in children with an initial ANA titer >1/160 and an age >10 years at AIC diagnosis. ANA screening should be recommended in children with AIC, and patients with ANA should be monitored long-term for SLE, with special attention to the transition period. This trial was registered at www.ClinicalTrials.gov as #NCT05937828., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
25. Mendelian Causes of Autoimmunity: the Lupus Phenotype.
- Author
-
Tusseau M, Khaldi-Plassart S, Cognard J, Viel S, Khoryati L, Benezech S, Mathieu AL, Rieux-Laucat F, Bader-Meunier B, and Belot A
- Subjects
- Humans, Male, Antigen-Antibody Complex, Genome-Wide Association Study, Phenotype, Female, Twin Studies as Topic, Autoimmunity genetics, Lupus Erythematosus, Systemic genetics
- Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized by its large heterogeneity in terms of clinical presentation and severity. The pathophysiology of SLE involves an aberrant autoimmune response against various tissues, an excess of apoptotic bodies, and an overproduction of type-I interferon. The genetic contribution to the disease is supported by studies of monozygotic twins, familial clustering, and genome-wide association studies (GWAS) that have identified numerous risk loci. In the early 70s, complement deficiencies led to the description of familial forms of SLE caused by a single gene defect. High-throughput sequencing has recently identified an increasing number of monogenic defects associated with lupus, shaping the concept of monogenic lupus and enhancing our insights into immune tolerance mechanisms. Monogenic lupus (moSLE) should be suspected in patients with either early-onset lupus or syndromic lupus, in male, or in familial cases of lupus. This review discusses the genetic basis of monogenic SLE and proposes its classification based on disrupted pathways. These pathways include defects in the clearance of apoptotic cells or immune complexes, interferonopathies, JAK-STATopathies, TLRopathies, and T and B cell dysregulations., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
26. Brain 18 F-FDG PET reveals cortico-subcortical hypermetabolic dysfunction in juvenile neuropsychiatric systemic lupus erythematosus.
- Author
-
Rodrigo S, Costi S, Ellul P, Aubart M, Boddaert N, Auvin S, Elmaleh M, Ntorkou A, Bader-Meunier B, Lebon V, Melki I, and Chiron C
- Abstract
Background: In juvenile systemic lupus erythematosus (j-SLE) with neuropsychiatric (NP) symptoms, there is a lack of diagnostic biomarkers. Thus, we study whether PET-FDG may identify any metabolic dysfunction in j-NPSLE., Methods: A total of 19
18 FDG-PET exams were consecutively performed using PET-MRI system in 11 non-sedated patients presenting with j-NPSLE (11-18y) for less than 18 months (m) and without any significant lesion at MRI. Psychiatric symptoms were scored from 0 (none) to 3 (severe) at PET time. PET images were visually analyzed and voxel-based analyses of cerebral glucose metabolism were performed using statistical parametric mapping (spm) with an age-matched control group, at threshold set > 50 voxels using both p < 0.001 uncorrected (unc.) and p < 0.05 corrected family wise error (FWE)., Results: Patients exhibited mainly psychiatric symptoms, with diffuse inflammatory j-NPSLE. First PET (n = 11) was performed at a mean of 15y of age, second/third PET (n = 7/n = 1) 6 to 19 m later. PET individual analysis detected focal bilateral anomalies in 13/19 exams visually but 19/19 using spm (unc.), mostly hypermetabolic areas (18/19). A total of 15% of hypermetabolic areas identified by spm had been missed visually. PET group analysis (n = 19) did not identify any hypometabolic area, but a large bilateral cortico-subcortical hypermetabolic pattern including, by statistical decreasing order (unc.), thalamus, subthalamic brainstem, cerebellum (vermis and cortex), basal ganglia, visual, temporal and frontal cortices. Mostly the subcortical hypermetabolism survived to FWE analysis, being most intense and extensive (51% of total volume) in thalamus and subthalamus brainstem. Hypermetabolism was strictly subcortical in the most severe NP subgroup (n = 8, scores 2-3) whereas it also extended to cerebral cortex, mostly visual, in the less severe subgroup (n = 11, scores 0-1), but difference was not significant. Longitudinal visual analysis was inconclusive due to clinical heterogeneity., Conclusions: j-NPSLE patients showed a robust bilateral cortico-subcortical hypermetabolic network, focused subcortically, particularly in thalamus, proportionally to psychiatric features severity. Further studies with larger, but homogeneous, cohorts are needed to determine the sensitivity and specificity of this dysfunctional pattern as a potential biomarker in diffuse inflammatory j-NPSLE with normal brain MRI., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
27. Juvenile neuropsychiatric systemic lupus erythematosus: A specific clinical phenotype and proposal of a probability score.
- Author
-
Labouret M, Trebossen V, Ntorkou A, Bartoli S, Aubart M, Auvin S, Bader-Meunier B, Baudouin V, Corseri O, Dingulu G, Ducrocq C, Dumaine C, Elmaleh M, Fabien N, Faye A, Hau I, Hentgen V, Kwon T, Meinzer U, Ouldali N, Parmentier C, Pouletty M, Renaldo F, Savioz I, Benoist JF, Le Roux E, Ellul P, and Melki I
- Subjects
- Humans, Child, Retrospective Studies, Brain diagnostic imaging, Brain pathology, Magnetic Resonance Imaging methods, Hallucinations complications, Hallucinations pathology, Lupus Vasculitis, Central Nervous System pathology, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic pathology
- Abstract
Objective: Juvenile systemic lupus erythematosus (j-SLE) is a rare chronic auto-immune disease involving several organs. Neuropsychiatric (NP) SLE (NPSLE) is frequent in j-SLE and associated with increased morbidity/mortality. Although NPSLE classification criteria exist, attributing NP features to j-SLE remains a major challenge. The study objective is to thoroughly describe j-NPSLE patients and assist in their diagnosis., Methods: This is a 4-year retrospective monocentric study of j-SLE patients. NP events were attributed to j-SLE using standardised diagnostic criteria and multidisciplinary paediatric clinical expertise. Clinical features, brain magnetic resonance imaging (MRI)s and samples analysis including cerebrospinal fluid were assessed. A risk of j-NPSLE score was developed based on multivariable logistic regression analysis., Results: Of 39 patients included, 44% were identified as having j-NPSLE. J-NPSLE diagnosis was established at the onset of j-SLE in 59% of patients. In addition to frequent kidney involvement (76%) and chilblains (65%), all j-NPSLE patients displayed psychiatric features: cognitive symptoms (82%), hallucinations (76%), depressed mood (35%), acute confused state (18%) and catatonia (12%). Neurological involvement was often mild and nonspecific, with headache (53%) in about half of the patients. The main features reported on brain MRI were nonspecific T2/FLAIR white matter hyperintensities (65%), and cerebral atrophy (88%). Upon immunosuppressive treatment, clinical improvement of NP features was observed in all j-NPSLE patients. The score developed to attribute j-NPSLE probability, guide further investigations and appropriate treatments is based on hallucinations, memory, sleep and renal involvement (Sensitivity: 0.95 Specificity: 0.85). Cerebrospinal fluid (CSF) neopterin assessment increases the score sensitivity and specificity., Conclusion: Physicians should carefully and systematically assess the presence of NP features at diagnosis and early stages of j-SLE. For j-NPSLE patients with predominant psychiatric features, a multidisciplinary collaboration, including psychiatrists, is essential for the diagnosis, management and follow-up., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
28. Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variants.
- Author
-
Bloch C, Jais JP, Gil M, Boubaya M, Lepelletier Y, Bader-Meunier B, Mahlaoui N, Garcelon N, Lambotte O, Launay D, Larroche C, Lazaro E, Liffermann F, Lortholary O, Michel M, Michot JM, Morel P, Cheminant M, Suarez F, Terriou L, Urbanski G, Viallard JF, Alcais A, Fischer A, de Saint Basile G, and Hermine O
- Subjects
- Adult, Humans, Adolescent, Alleles, Genotype, Signaling Lymphocytic Activation Molecule Associated Protein genetics, X-Linked Inhibitor of Apoptosis Protein genetics, Lymphohistiocytosis, Hemophagocytic genetics, Lymphohistiocytosis, Hemophagocytic therapy
- Abstract
Background: The contribution of genetic factors to the severity of adult hemophagocytic lymphohistiocytosis (HLHa) remains unclear., Objective: We sought to assess a potential link between HLHa outcomes and HLH-related gene variants., Methods: Clinical characteristics of 130 HLHa patients (age ≥ 18 years and HScore ≥ 169) and genotype of 8 HLH-related genes (LYST, PRF1, UNC13-D, STX11, STXBP2, RAB27A, XIAP, and SAP) were collected. A total of 34 variants found in only 6 genes were selected on the basis of their frequency and criteria predicted to impair protein function. Severity was defined by refractory disease to HLH treatment, death, or transfer to an intensive care unit., Results: HLHa-associated diseases (ADs) were neoplasia (n = 49 [37.7%]), autoimmune/inflammatory disease (n = 33 [25.4%]), or idiopathic when no AD was identified (n = 48 [36.9%]). Infectious events occurred in 76 (58.5%) patients and were equally distributed in all ADs. Severe and refractory HLHa were observed in 80 (61.5%) and 64 (49.2%) patients, respectively. HScore, age, sex ratio, AD, and infectious events showed no significant association with HLHa severity. Variants were identified in 71 alleles and were present in 56 (43.1%) patients. They were distributed as follows: 44 (34.4%), 9 (6.9%), and 3 (2.3%) patients carrying 1, 2, and 3 variant alleles, respectively. In a logistic regression model, only the number of variants was significantly associated with HLHa severity (1 vs 0: 3.86 [1.73-9.14], P = .0008; 2-3 vs 0: 29.4 [3.62-3810], P = .0002) and refractoriness (1 vs 0: 2.47 [1.17-5.34], P = .018; 2-3 vs 0: 13.2 [2.91-126.8], P = .0003)., Conclusions: HLH-related gene variants may be key components to the severity and refractoriness of HLHa., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.